loadpatents
Patent applications and USPTO patent grants for King; David John.The latest application filed is for "human antibodies that bind cd22 and uses thereof".
Patent | Date |
---|---|
Human Antibodies That Bind Cd22 And Uses Thereof App 20170058031 - King; David John ;   et al. | 2017-03-02 |
Human antibodies that bind CD22 and uses thereof Grant 9,499,632 - King , et al. November 22, 2 | 2016-11-22 |
Human Antibodies That Bind Cd22 And Uses Thereof App 20130230530 - King; David John ;   et al. | 2013-09-05 |
Human antibodies that bind CD22 and uses thereof Grant 8,481,683 - King , et al. July 9, 2 | 2013-07-09 |
Human monoclonal antibodies to CD70 Grant 8,124,738 - Terret , et al. February 28, 2 | 2012-02-28 |
CD19 antibodies and their uses Grant 8,097,703 - Rao-Naik , et al. January 17, 2 | 2012-01-17 |
Divalent antibody fragments Grant 8,067,005 - Chapman , et al. November 29, 2 | 2011-11-29 |
Methods of treating cancer with an antibody-drug conjugate Grant 8,034,959 - Ng , et al. October 11, 2 | 2011-10-11 |
Antibody molecules specific to human tumour necrosis factor alpha Grant 7,977,464 - Athwal , et al. July 12, 2 | 2011-07-12 |
Antibodies to treat cancer Grant 7,781,569 - Fanger , et al. August 24, 2 | 2010-08-24 |
Human Antibodies That Bind Cd70 And Uses Thereof App 20100150950 - Coccia; Marco A. ;   et al. | 2010-06-17 |
Human Antibodies That Bind Cd22 And Uses Thereof App 20100143368 - King; David John ;   et al. | 2010-06-10 |
Human Antibodies That Bind Cd19 And Uses Thereof App 20100104509 - King; David John ;   et al. | 2010-04-29 |
Human Monoclonal Antibodies to Prostate Specific Membrane Antigen (PSMA) App 20090297438 - Huang; Haichun ;   et al. | 2009-12-03 |
CD19 Antibodies And Their uses App 20090142349 - Rao-Naik; Chetana ;   et al. | 2009-06-04 |
Human Monoclonal Antibodies To Cd70 App 20090028872 - Terret; Jonathan Alexander ;   et al. | 2009-01-29 |
Antibody-Drug Conjugates and Methods of Use App 20080279868 - Boyd; Sharon Elaine ;   et al. | 2008-11-13 |
Biological Products App 20080269465 - ATHWAL; DILJEET SINGH ;   et al. | 2008-10-30 |
Antibody molecules specific to human tumor necrosis factor alpha Grant 7,402,662 - Athwal , et al. July 22, 2 | 2008-07-22 |
Production of humanised antibodies to TNF.alpha. Grant 7,186,820 - Athwal , et al. March 6, 2 | 2007-03-06 |
Biological products App 20060233800 - Athwal; Diljeet Singh ;   et al. | 2006-10-19 |
Biological products Grant 7,012,135 - Athwal , et al. March 14, 2 | 2006-03-14 |
Monovalent antibody fragments App 20040121415 - King, David John ;   et al. | 2004-06-24 |
Multivalent Antigen-binding Proteins App 20030148406 - KING, DAVID JOHN ;   et al. | 2003-08-07 |
Biological products App 20030026805 - Athwal, Diljeet Singh ;   et al. | 2003-02-06 |
Tri- and tetra-valent monospecific antigen-binding proteins Grant 6,511,663 - King , et al. January 28, 2 | 2003-01-28 |
Biological products App 20020151682 - Athwal, Diljeet Singh ;   et al. | 2002-10-17 |
Humanized antibodies directed against A33 antigen Grant 6,307,026 - King , et al. October 23, 2 | 2001-10-23 |
Multivalent antigen-binding proteins Grant 5,864,019 - King , et al. January 26, 1 | 1999-01-26 |
SEC | 0001684902 | King David John |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.